FDA Approves First Gene Therapy for Inherited Hearing Loss

On April 23, 2026, the U.S. Food and Drug Administration (FDA) approved the first gene therapy for inherited hearing loss, specifically targeting a rare genetic mutation in the OTOF gene. This condition affects approximately 50 infants born each year in the United States. The therapy, named Otarmeni, has shown significant promise in clinical trials, where 16 out of 20 children experienced improvements in hearing within five months post-treatment. Notably, five of the 12 children monitored for over 11 months achieved near-normal hearing levels.

CNN

Parents of children who participated in the clinical trials have expressed profound gratitude for the therapy's impact. Kerri, the mother of a trial participant, described the experience as "miraculous," highlighting the transformation from her son being profoundly deaf to hearing alongside his peers. This emotional testimony underscores the therapy's potential to change lives dramatically.

CNN

Regeneron, the biotechnology company behind Otarmeni, announced that the therapy will be provided free of charge to patients in the United States. Dr. George Yancopoulos, co-founder and president of Regeneron, emphasized the company's intention to set a precedent in the biotech industry by making this life-changing treatment accessible. The FDA's expedited review process for Otarmeni was part of a new National Priority Voucher program aimed at accelerating the availability of critical therapies.

CNN

The administration of Otarmeni involves a surgical procedure akin to cochlear implantation. While the clinical trials indicated the therapy's safety, potential side effects may arise from the surgical aspect rather than the gene therapy itself. Regeneron has indicated plans to seek regulatory approval for Otarmeni in other countries, although it has not confirmed whether the therapy will be offered free to patients outside the U.S.

CNN

Despite the positive reception of Otarmeni, some concerns remain regarding the broader implications of gene therapy pricing and accessibility in different markets. The company has not disclosed whether similar pricing strategies will be implemented internationally, which raises questions about equitable access to such groundbreaking treatments.

CNN

Dr. Marty Makary, FDA Commissioner, praised the swift approval of Otarmeni, highlighting the agency's commitment to expediting access to innovative therapies. Regeneron’s approach to pricing has been framed as a model for future biotech developments, aiming to align U.S. drug prices with those in Europe and Asia.

CNN

• “You go from being told your child’s profoundly deaf and may only ever hear with technology to your child’s hearing right alongside his friends. … This is just amazing.” — Kerri, Mother of Clinical Trial Participant

CNN

• “We want to make an example of how science, and in this case biotech, can really deliver a gift to people – in this case, the gift of hearing,” — Dr. George Yancopoulos, Co-founder and President of Regeneron

CNN

The approval of Otarmeni marks a significant milestone in the treatment of inherited hearing loss, offering hope to families affected by this rare condition while raising important discussions about accessibility and pricing in the field of gene therapy.

CNN